D. P. Ryan

629 citations

31 papers · 510 indexed · h-index 13

Oncology top 10%
- Colorectal Cancer Treatments and Studies 9
- Pancreatic and Hepatic Oncology Research 6
- Cancer Treatment and Pharmacology 4
Cancer Research
- Cancer Genomics and Diagnostics 4
Pulmonary and Respiratory Medicine
- Lung Cancer Treatments and Mutations 6
- Gastric Cancer Management and Outcomes 4
Hepatology
Toxicology
Surgery
- Colorectal and Anal Carcinomas 6
Epidemiology
- Neuroendocrine Tumor Research Advances 3

Co-authors: S. W. Serjeantson Lawrence S. Blaszkowsky Arthur R. Thompson Jeffrey G. Supko J. P. Eder Andrew X. Zhu J. A. Meyerhardt Michael V. Seiden
Cited by: Oncology Cancer Research Pulmonary and Respiratory Medicine
Journals: Journal of Clinical Oncology (17 papers)International Journal of Radiation Oncology*Biology*Physics (3 papers)The Medical Journal of Australia (2 papers)
Partner nations: United States Australia Netherlands

In The Last Decade

D. P. Ryan

29 papers receiving 479 citations

Peers

Countries citing papers authored by D. P. Ryan

Since Specialization

Citations

This map shows the geographic impact of D. P. Ryan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. P. Ryan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. P. Ryan more than expected).

Fields of papers citing papers by D. P. Ryan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. P. Ryan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. P. Ryan. The network helps show where D. P. Ryan may publish in the future.

Co-authorship network

The 25 scholars most cited alongside D. P. Ryan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with D. P. Ryan Line = papers co-authored together D. P. Ryan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Long-Term Outcomes of Definitive Chemoradiation with Proton Therapy for Treatment of Carcinoma of the Anal Canal: Combined Analysis of Two Prospective Trials International Journal of Radiation OncologyBiologyPhysics ·Yanedt Raquel,Editors John Mac ntyre,Julie L. Koenig,John P. Plastaras,Amias Bushe,B.Y. Yeap,Lorraine C. Drapek,Christian Baglini,D. P. Ryan,Eduarda Rodrigues Pagliarini,Jill N. Allen,John W. Clark,Lawrence S. Blaszkowsky,Edgar Ben‐Josef,Y. C. Chen,Jordan Kharofa,Irina Ramanandraitsiory	2024	0
2	Clinical staging in pancreatic adenocarcinoma underestimates extent of disease HPB ·A. Saiju,大隆鈴木,Keith D. Lillemoe,D. P. Ryan,Theodore S. Hong,Lawrence S. Blaszkowsky,Carlos Fernández del Castillo,Motaz Qadan	2019	3
3	Clinical and Treatment Factors Associated With Vaginal Stenosis After Definitive Chemoradiation for Anal Cancer International Journal of Radiation OncologyBiologyPhysics ·Renato Hikawa,Y. C. Chen,Marek Ancukiewicz,D. P. Ryan,Lawrence S. Blaszkowsky,Lorraine C. Drapek,James C. Cusack,Lisa A. Kachnic,Jennifer Y. Wo	2013	0
4	Updated results of a phase I study of pasireotide (SOM230) in combination with everolimus (RAD001) in patients (pts) with advanced neuroendocrine tumors (NET). Journal of Clinical Oncology ·Jennifer A. Chan,D. P. Ryan,Christiane Fuchs,Andrew X. Zhu,Thomas A. Abrams,Brian M. Wolpin,Paige Malinowski,Eileen Regan,Michael Kulke	2011	10
5	Randomized phase II study of the efficacy and safety of gemcitabine plus TH-302 versus gemcitabine alone in previously untreated patients with advanced pancreatic cancer. Journal of Clinical Oncology ·Mitesh J. Borad,Darren Sigal,Hope E. Uronis,Joseph Stephenson,Nathan Bahary,Mark U. Rarick,Linda C. DeMarco,Yuhan Chen,E. Gabriela Chiorean,D. P. Ryan,Allen Lee Cohn,Brian Ulrich,王达丰,E. Anderes,Dídac Piferrer Serrano,Peter Paul Yu,Frank A. Sinicrope,Charis Eng,R.I. OSIKINA,AMELIA CHRISTMAS	2011	5
6	A single-arm trial of panitumumab in cetuximab refractory KRAS wild-type colorectal cancer. Journal of Clinical Oncology ·Raymond Wadlow,Aram F. Hezel,Brian M. Wolpin,Liu Shufen,Lawrence S. Blaszkowsky,E.L. Kwak,Rawian Rafizah,Andrew X. Zhu,D. P. Ryan,J. W. Clark	2011	3
7	The effect of neoadjuvant chemoradiation therapy on the prognostic value of lymph nodes after rectal cancer surgery The American Journal of Surgery ·E. Cleator,Paul C. Shellito,David W. Rattner,Richard A. Hodin,James C. Cusack,Liliana Bordeianou,Patricia Sylla,Theodore S. Hong,Lawrence S. Blaszkowsky,D. P. Ryan,Gregory Y. Lauwers,Yuchiao Chang,David L. Berger	2010	23
8	Dose-painted intensity-modulated radiation therapy for anal cancer: A multi-institutional report of acute toxicity and response to therapy. Journal of Clinical Oncology ·Theodore S. Hong,H.K. Tsai,John J. Coen,Lawrence S. Blaszkowsky,Kevan L. Hartshorn,E.L. Kwak,Hanan Amaireh,D. P. Ryan,Lisa A. Kachnic	2010	7
9	Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer Annals of Oncology ·Peter C. Enzinger,D. P. Ryan,J. W. Clark,Alona Muzikansky,Craig C. Earle,Matthew H. Kulke,Jeffrey A. Meyerhardt,Lawrence S. Blaszkowsky,Andrew X. Zhu,P. Fidias,Michele Vincitore,Robert J. Mayer,Charles S. Fuchs	2009	16
10	Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer Journal of Clinical Oncology ·Peter C. Enzinger,D. P. Ryan,Eileen Regan,Paul-Laurent Assoun,Thomas A. Abrams,Aram F. Hezel,P. Fidias,Lecia V. Sequist,Lawrence S. Blaszkowsky,Charles S. Fuchs	2008	36
11	Phase II study of RAD001 in previously treated patients with metastatic pancreatic cancer Journal of Clinical Oncology ·Brian M. Wolpin,Aram F. Hezel,D. P. Ryan,Thomas A. Abrams,J. A. Meyerhardt,Lawrence S. Blaszkowsky,J. W. Clark,Benjamin Allen,Eileen Regan,Charles S. Fuchs	2008	9
12	A phase I dose-finding study of sunitinib (SU) in combination with gemcitabine (G) in patients (pts) with advanced solid tumors Journal of Clinical Oncology ·M. Dror Michaelson,Max Andreani,D. P. Ryan,David F. McDermott,Geoffrey I. Shapiro,L. Tye,Joel Ojok,Paulina Selaru,HEEJUN SON,肇徳永	2008	4
13	Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastastic colorectal cancer Annals of Oncology ·J. A. Meyerhardt,Keith Stuart,Christiane Fuchs,Andrew X. Zhu,C. Suárez‐Plascencia,Pankaj Bhargava,Lawrence S. Blaszkowsky,Peter C. Enzinger,R. Mayer,Kurniati Rahmadani,C. Lawrence,D. P. Ryan	2007	63
14	Phase I trial of ARQ 501, an Activated Checkpoint Therapy (ACT) agent, in patients with advanced solid tumors Journal of Clinical Oncology ·Geoffrey I. Shapiro,Jeffrey G. Supko,D. P. Ryan,L. M. Appelman,Anna Berkenblit,Adam R. Craig,Juan Sebastián Vittone,Lucy Katerin Diaz-Acho,Kathleen M. Elmore,J. P. Eder	2005	21
15	Phase I study of neoadjuvant bevacizumab, 5-fluorouracil, and radiation therapy followed by surgery for patients with primary rectal cancer Journal of Clinical Oncology ·Christopher G. Willett,Toru Aratani,D. Sahani,Masanobu Mino,J. W. Clark,D. P. Ryan,Andrew X. Zhu,Wiggin,Gregory Y. Lauwers,邓伦华 Deng Lunhua	2004	14
16	A phase I/II study of preoperative oxaliplatin (O), 5-fluorouracil (5-FU), and external beam radiation therapy (XRT) in locally advanced rectal cancer: CALGB 89901 Journal of Clinical Oncology ·D. P. Ryan,Donna Niedzwiecki,Donna Hollis,Diane Grenier,Scott Wadler,Joel E. Tepper,Ruth J. Mayer	2004	1
17	Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC) Journal of Clinical Oncology ·J. A. Meyerhardt,Mesut Pekcan,Peter C. Enzinger,D. P. Ryan,Jeffrey W. Clark,Matthew H. Kulke,Ann Michelini,Michele Vincitore,Annette Thomas,Charles S. Fuchs	2004	2
18	Phase I trials with ET-743, a marine derived (MD) anticancer agent European Journal of Cancer ·Gerald R. Black,J.L. Misset,Miguel A. Villalona‐Calero,D. P. Ryan,J. Clark,Jos H. Beijnen,Piotr Eder,Jeffrey G. Supko,A. Bowman,SafaaA Ghobashy,Huei-Lin Lue,Esteban Cvitkovic,C. Guzmán,Li Song	1999	1
19	Refinements in Pediatric Microtia Reconstruction Archives of Otolaryngology - Head and Neck Surgery ·Roland D. Eavey,D. P. Ryan	1996	20
20	HLA antigens in four Pacific populations with non-insulin-dependent diabetes mellitus Annals of Human Biology ·S. W. Serjeantson,D. P. Ryan,Paul Zimmet,Richard Taylor,Rebecca Cross,Neciosup Arribasplata,Ningte Yan	1982	21

About D. P. Ryan

D. P. Ryan is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Toxicology and Surgery, having authored 31 papers that have together received 510 indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (9 papers), Pancreatic and Hepatic Oncology Research (6 papers), Colorectal and Anal Carcinomas (6 papers), Lung Cancer Treatments and Mutations (6 papers), Cancer Treatment and Pharmacology (4 papers), Cancer Genomics and Diagnostics (4 papers), Gastric Cancer Management and Outcomes (4 papers) and Neuroendocrine Tumor Research Advances (3 papers). The work is most often cited by research in Oncology (241 citations), Cancer Research (83 citations), Pulmonary and Respiratory Medicine (180 citations), Hepatology (34 citations) and Toxicology (14 citations). D. P. Ryan has collaborated with scholars based in United States, Australia and Netherlands. Frequent co-authors include S. W. Serjeantson, Lawrence S. Blaszkowsky, Arthur R. Thompson, Jeffrey G. Supko, J. P. Eder, Andrew X. Zhu, J. A. Meyerhardt, Michael V. Seiden, Peter C. Enzinger and Thomas J. Lynch. Their work appears in journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics, The Medical Journal of Australia, Annals of Oncology and Annals of Human Biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact